Q2 EPS Estimate for Astria Therapeutics Lowered by Analyst

Astria Therapeutics, Inc. (NASDAQ:ATXS) – Stock analysts at HC Wainwright dropped their Q2 2025 earnings estimates for shares of Astria Therapeutics in a note issued to investors on Wednesday, May 14th. HC Wainwright analyst J. Pantginis now anticipates that the biotechnology company will post earnings per share of ($0.67) for the quarter, down from their previous forecast of ($0.50). HC Wainwright has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for Astria Therapeutics’ current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Astria Therapeutics’ Q3 2025 earnings at ($0.69) EPS, Q4 2025 earnings at ($0.76) EPS, FY2025 earnings at ($2.70) EPS, FY2026 earnings at ($2.42) EPS, FY2027 earnings at ($2.51) EPS and FY2028 earnings at ($2.16) EPS.

Other research analysts have also issued reports about the stock. JMP Securities began coverage on shares of Astria Therapeutics in a research note on Friday, January 31st. They issued an “outperform” rating and a $26.00 price objective on the stock. Citizens Jmp upgraded shares of Astria Therapeutics to a “strong-buy” rating in a research note on Friday, January 31st. Wedbush restated an “outperform” rating and issued a $28.00 price objective (up from $27.00) on shares of Astria Therapeutics in a research note on Wednesday, March 12th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $47.00 price objective on shares of Astria Therapeutics in a research note on Wednesday. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $30.00.

Astria Therapeutics Stock Performance

NASDAQ ATXS opened at $3.96 on Friday. The firm has a market cap of $223.48 million, a PE ratio of -1.89 and a beta of 0.45. Astria Therapeutics has a one year low of $3.56 and a one year high of $12.92. The firm’s fifty day moving average is $5.01 and its two-hundred day moving average is $7.40.

Astria Therapeutics (NASDAQ:ATXS) last announced its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.10).

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. KLP Kapitalforvaltning AS acquired a new position in shares of Astria Therapeutics during the fourth quarter worth about $41,000. GAMMA Investing LLC increased its holdings in Astria Therapeutics by 1,127.4% in the first quarter. GAMMA Investing LLC now owns 8,678 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 7,971 shares in the last quarter. Brooklyn Investment Group increased its holdings in Astria Therapeutics by 1,079.6% in the first quarter. Brooklyn Investment Group now owns 8,694 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 7,957 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in Astria Therapeutics by 109.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 2,766 shares in the last quarter. Finally, BNP Paribas Financial Markets purchased a new position in Astria Therapeutics in the fourth quarter valued at about $50,000. 98.98% of the stock is currently owned by institutional investors and hedge funds.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.